Brought to you by 
China's 3SBio closes $107mm IPO
15 Mar 2007
Executive Summary
Chinese drug developer 3SBio (protein-based therapeutics for nephrology and oncology) completed its initial public offering in the US, netting $107mm through the sale of 7.7mm American Depository Shares at $16 apiece (it had anticipated $12-16); each ADS represents seven ordinary shares.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
China's 3SBio closes $107mm IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice